356 related articles for article (PubMed ID: 22024525)
1. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
[TBL] [Abstract][Full Text] [Related]
3. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
[TBL] [Abstract][Full Text] [Related]
4. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
[TBL] [Abstract][Full Text] [Related]
5. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
[TBL] [Abstract][Full Text] [Related]
7. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
8. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
[TBL] [Abstract][Full Text] [Related]
9. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
11. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy.
Cento V; Landonio S; De Luca F; Di Maio VC; Micheli V; Mirabelli C; Niero F; Magni C; Rizzardini G; Perno CF; Ceccherini-Silberstein F
Antivir Ther; 2013; 18(4):645-8. PubMed ID: 23411358
[TBL] [Abstract][Full Text] [Related]
12. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
[TBL] [Abstract][Full Text] [Related]
13. NS3 protease of genotype 3 subtype h HCV identified in southeastern France.
Colson P; Gayet S; Gerolami R
Antivir Ther; 2011; 16(4):615-9. PubMed ID: 21685551
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients.
Khan HU; Khan S; Shah MA; Attaullah S; Malik MA
PLoS One; 2020; 15(4):e0231480. PubMed ID: 32275694
[TBL] [Abstract][Full Text] [Related]
16. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
18. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.
Besse B; Coste-Burel M; Bourgeois N; Feray C; Imbert-Marcille BM; André-Garnier E
J Virol Methods; 2012 Oct; 185(1):94-100. PubMed ID: 22728274
[TBL] [Abstract][Full Text] [Related]
19. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
